Cancer metabolism based therapeutics help alter the energy producing pathways in cancer cells to kill tumors or make them more responsive to other anti-cancer treatments. Targeting cancer cell metabolism allows oncologists to cut off fuel supply to tumors, starving them and halting their growth and spread. Products such as adenosine triphosphate (ATP) competitive inhibitors, which block certain enzymes involved in generating cellular energy are being studied.
The global cancer metabolism based therapeutics market is estimated to be valued at US$ 210.2 Bn in 2023 and is expected to exhibit a CAGR of 95.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the cancer metabolism based therapeutics market is the increasing number of clinical trials focused on investigating the effectiveness of metabolic inhibitors. For instance, Phase I and II clinical trials are investigating drugs such as AZD3965 by AstraZeneca that targets certain metabolic enzymes. Another trend is the rise in funding and investments by pharmaceutical companies as well as government bodies in research analyzing cancer cell metabolism pathways. This is leading to the development of more effective and targeted drugs that interfere with cancer cell metabolism. Researchers are also exploring combination therapies that involve using metabolic inhibitors along with chemotherapy or other targeted therapies to enhance anti-tumor effects.
Porter’s Analysis
Threat of new entrants: Low threat due to high capital requirement and presence of established players in the market.
Bargaining power of buyers: Moderate bargaining power due to availability of alternatives.
Bargaining power of suppliers: High bargaining power due to limited availability of raw materials and expertise required.
Threat of new substitutes: Low threat as cancer metabolism based therapeutics provide innovative approach.
Competitive rivalry: High competitive rivalry due to presence of major established players.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/cancer-metabolism-based-therapeutics-market-961
Key Takeaways
The global Cancer Metabolism Based Therapeutics Market is expected to witness high growth. Regional analysis comprises Regional analysis related content
The Cancer Metabolism Based Therapeutics Market in North America is expected to hold the largest share and grow at a highest CAGR during the forecast period. Factors such as increasing healthcare expenditure, growing awareness regarding novel therapeutics, and presence of key players in the region are expected to drive the market.
Key players operating in the Cancer Metabolism Based Therapeutics Market are Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca. Calithera Biosciences, Inc focuses on developing therapies for cancer metabolism. Celgene Corporation develops innovative cancer metabolism disrupting therapies.
